Martek Stock Climbs 45%; Do Future Gains Lie Beyond Infant Formula?
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences' long-awaited launch of its DHA and ARA nutritional oils in U.S. infant formula has garnered Wall Street's enthusiasm, but continued investor confidence could hinge on the fortified products' commercial success, as well as Martek's ability to expand beyond the infant formula market
You may also be interested in...
LCP-Fortified Formula Reduces Abnormal Infant Movement -Dutch Study
Formula fortified with long-chain polyunsaturated fatty acids may bolster neurological development in infants, as measured by abnormal general movements, a study published in the August American Journal of Clinical Nutrition concludes
LCP-Fortified Formula Reduces Abnormal Infant Movement -Dutch Study
Formula fortified with long-chain polyunsaturated fatty acids may bolster neurological development in infants, as measured by abnormal general movements, a study published in the August American Journal of Clinical Nutrition concludes
LCP-Fortified Formula Reduces Abnormal Infant Movement -Dutch Study
Formula fortified with long-chain polyunsaturated fatty acids may bolster neurological development in infants, as measured by abnormal general movements, a study published in the August American Journal of Clinical Nutrition concludes